Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference

PR Newswire January 4, 2021

Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference

PR Newswire November 19, 2020

Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

PR Newswire November 10, 2020

Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment

PR Newswire November 9, 2020

Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PR Newswire October 26, 2020

Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

PR Newswire September 9, 2020

Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

PR Newswire August 12, 2020

Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020

PR Newswire June 22, 2020

Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th

PR Newswire June 8, 2020

Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity

PR Newswire May 29, 2020

Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020

PR Newswire May 14, 2020

Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

PR Newswire May 12, 2020

Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020

PR Newswire May 4, 2020

Phio Pharmaceuticals Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market

PR Newswire April 2, 2020

Phio Pharmaceuticals Announces $4.0 Million Registered Direct Offering Priced At-the-Market

PR Newswire March 31, 2020

Phio Announces Positive New Data Validating the INTASYL(TM) Immunotherapy Platform's Ability to Develop Novel Compounds Capable of Inhibiting Cancer Tumor Growth

PR Newswire March 31, 2020

Phio Pharmaceuticals Reports Year End 2019 Financial Results and Provides Business Update

PR Newswire March 26, 2020

Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene

PR Newswire March 10, 2020

Phio Pharmaceuticals Announces Closing of $8.0 Million Underwritten Public Offering

PR Newswire February 13, 2020

Phio Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

PR Newswire February 11, 2020